MIST
Milestone Pharmaceuticals Inc
$
1.710
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.780
Open
1.710
VWAP
1.69
Vol
1.54M
Mkt Cap
145.34M
Low
1.650
Amount
2.60M
EV/EBITDA(TTM)
--
Total Shares
53.26M
EV
157.11M
EV/OCF(TTM)
--
P/S(TTM)
--
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
--
--
-0.295
-4.84%
--
--
-0.203
+7.02%
--
--
-0.167
+19.05%
Estimates Revision
The market is revising No Change the revenue expectations for Milestone Pharmaceuticals Inc. (MIST) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 10.32%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+10.32%
In Past 3 Month
3 Analyst Rating
Wall Street analysts forecast MIST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIST is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.710
Low
4.00
Averages
4.50
High
5.00
Current: 1.710
Low
4.00
Averages
4.50
High
5.00
Wells Fargo
Overweight
initiated
$4
2025-09-11
Reason
Wells Fargo
Price Target
$4
2025-09-11
initiated
Overweight
Reason
Wells Fargo initiated coverage of Milestone Pharmaceuticals with an Overweight rating and $4 price target. The company is developing Etripamil, a nasal administered, short-acting, calcium channel blocker for the treatment of paroxysmal supraventricular tachycardia, the analyst tells investors in a research note. The firm views Etripamil as "highly differentiated" versus the standard of care and sees the potential for it to emerge as one of the key drugs for acute treatment.
H.C. Wainwright
Brandon Folkes
initiated
$5
2025-06-05
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$5
2025-06-05
initiated
Reason
H.C. Wainwright analyst Brandon Folkes assumed coverage of Milestone Pharmaceuticals with a Buy rating and $5 price target. Milestone is developing Cardamyst for the treatment of paroxysmal supraventricular tachycardia, the analyst tells investors in a research note. The firm sees a path to resubmission in 2025, and a 2026 approval. The company's current enterprise value of $75M, ascribes a lower probability of resolving the complete response letter than is warranted, contends H.C. Wainwright.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Maintains
$25 → $10
2025-04-01
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$25 → $10
2025-04-01
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$25
2025-03-28
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$25
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$25
2025-03-17
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$25
2025-03-17
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$25
2025-02-28
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$25
2025-02-28
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Milestone Pharmaceuticals Inc (MIST.O) is -1.74, compared to its 5-year average forward P/E of -3.02. For a more detailed relative valuation and DCF analysis to assess Milestone Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.02
Current PE
-1.74
Overvalued PE
-1.57
Undervalued PE
-4.47
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.09
Undervalued EV/EBITDA
-2.97
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
46.52
Current PS
1.71
Overvalued PS
137.45
Undervalued PS
-44.42
Financials
Annual
Quarterly
FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY :
+28.83%
-12.53M
Operating Profit
FY2025Q2
YoY :
+38.48%
-12.97M
Net Income after Tax
FY2025Q2
YoY :
+42.86%
-0.20
EPS - Diluted
FY2025Q2
YoY :
+107.54%
-12.58M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
750.0K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
1
309.0K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MIST News & Events
Events Timeline
2025-11-03 (ET)
2025-11-03
08:21:57
Milestone Pharmaceuticals to Showcase New Trial Analysis for PSVT
2025-08-12 (ET)
2025-08-12
07:18:39
Milestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c)
2025-07-11 (ET)
2025-07-11
15:04:52
Milestone prices $52.5M common shares offering at $1.50 per share
Sign Up For More Events
Sign Up For More Events
News
1.0
10-09NewsfilterMilestone® Pharmaceuticals to Showcase Etripamil Data at the 2025 American Heart Association Scientific Sessions
9.5
08-12NewsfilterMilestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
4.5
07-11BenzingaCrude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
Sign Up For More News
People Also Watch
SOL
Emeren Group Ltd
1.890
USD
0.00%
BRAG
Bragg Gaming Group Inc
2.070
USD
-0.48%
ATOS
Atossa Therapeutics Inc
0.821
USD
+0.74%
SND
Smart Sand Inc
2.090
USD
-1.88%
FCAP
First Capital Inc
44.100
USD
-0.59%
UPLD
Upland Software Inc
1.720
USD
-6.52%
PETS
Petmed Express Inc
2.580
USD
+5.31%
VRA
Vera Bradley Inc
2.350
USD
0.00%
ECOR
electroCore, Inc.
5.830
USD
-0.17%
FAQ
What is Milestone Pharmaceuticals Inc (MIST) stock price today?
The current price of MIST is 1.71 USD — it has decreased -0.58 % in the last trading day.
What is Milestone Pharmaceuticals Inc (MIST)'s business?
What is the price predicton of MIST Stock?
What is Milestone Pharmaceuticals Inc (MIST)'s revenue for the last quarter?
What is Milestone Pharmaceuticals Inc (MIST)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Milestone Pharmaceuticals Inc (MIST)'s fundamentals?
How many employees does Milestone Pharmaceuticals Inc (MIST). have?